ZA201707464B - Multi-ligand drug conjugates and uses thereof - Google Patents

Multi-ligand drug conjugates and uses thereof

Info

Publication number
ZA201707464B
ZA201707464B ZA2017/07464A ZA201707464A ZA201707464B ZA 201707464 B ZA201707464 B ZA 201707464B ZA 2017/07464 A ZA2017/07464 A ZA 2017/07464A ZA 201707464 A ZA201707464 A ZA 201707464A ZA 201707464 B ZA201707464 B ZA 201707464B
Authority
ZA
South Africa
Prior art keywords
drug conjugates
ligand drug
ligand
conjugates
drug
Prior art date
Application number
ZA2017/07464A
Other languages
English (en)
Inventor
Baohua Robert Huang
Jian Dai
Zhongbo Wang
Xueyuan Xie
Xiaodong Liu
Xinli Hu
Original Assignee
Coherent Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510489556.6A external-priority patent/CN106466485B/zh
Priority claimed from CN201510489560.2A external-priority patent/CN106466484B/zh
Application filed by Coherent Biopharma filed Critical Coherent Biopharma
Publication of ZA201707464B publication Critical patent/ZA201707464B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2017/07464A 2015-08-11 2017-11-03 Multi-ligand drug conjugates and uses thereof ZA201707464B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510489556.6A CN106466485B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN201510489560.2A CN106466484B (zh) 2015-08-11 2015-08-11 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
PCT/CN2016/094704 WO2017025057A1 (en) 2015-08-11 2016-08-11 Multi-ligand drug conjugates and uses thereof

Publications (1)

Publication Number Publication Date
ZA201707464B true ZA201707464B (en) 2021-05-26

Family

ID=57983917

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/07464A ZA201707464B (en) 2015-08-11 2017-11-03 Multi-ligand drug conjugates and uses thereof

Country Status (13)

Country Link
US (2) US11571480B2 (enExample)
EP (1) EP3334500B1 (enExample)
JP (3) JP6772199B2 (enExample)
KR (2) KR102464778B1 (enExample)
CN (3) CN112263683A (enExample)
AU (2) AU2016305703B2 (enExample)
CA (1) CA2987322C (enExample)
DK (1) DK3334500T3 (enExample)
ES (1) ES2877409T3 (enExample)
MX (1) MX381031B (enExample)
RU (1) RU2722449C2 (enExample)
WO (1) WO2017025057A1 (enExample)
ZA (1) ZA201707464B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445932B1 (en) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
MX381031B (es) * 2015-08-11 2025-03-12 Coherent Biopharma | Ltd Conjugados fármaco-multiligando y usos de los mismos.
US20200384069A1 (en) * 2017-12-01 2020-12-10 Soricimed Biopharma Inc. Trpv6 inhibitors and combination therapies for treating cancers
EP3720842A4 (en) * 2017-12-06 2021-11-03 Ontario Institute For Cancer Research ACYLHYDRAZONE LINKERS, METHODS, AND USES THEREOF
US11850287B2 (en) 2017-12-22 2023-12-26 Ontario Institute For Cancer Search (Oicr) Heterocyclic acyl hydrazone linkers, methods and uses thereof
WO2019134018A1 (en) * 2018-01-05 2019-07-11 Telethon Kids Institute Vaccine conjugates and uses thereof
SG11202108182RA (en) * 2019-01-30 2021-08-30 Coherent Biopharma Suzhou Limited Bi-ligand drug conjugate and use thereof
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use
JP7523526B2 (ja) * 2019-08-20 2024-07-26 チンタオ エムジーアイ テック カンパニー リミテッド 発光標識及び二次発光信号の光信号速度論に基づくポリヌクレオチドの配列決定方法
JP2023514240A (ja) * 2020-02-13 2023-04-05 エスケープ・セラピューティクス・インコーポレイテッド 黒色腫治療薬
US20240058478A1 (en) * 2021-01-07 2024-02-22 Purdue Research Foundation Folate receptor-targeted conjugates, compositions, and delivery to the central nervous system
CN117693365A (zh) * 2021-06-25 2024-03-12 同宜医药（苏州）有限公司 配体药物偶联物及其应用
CN116059392B (zh) * 2021-09-03 2025-02-28 同宜医药（苏州）有限公司 配体偶联物及其应用
WO2023036193A1 (zh) * 2021-09-08 2023-03-16 同宜医药（苏州）有限公司 药物制剂及其制备方法和用途
AU2022371507A1 (en) * 2021-10-19 2024-05-02 Coherent Biopharma (Suzhou) Limited Conjugate drug preparation, preparation method therefor and use thereof
CN116196408A (zh) * 2021-12-30 2023-06-02 思格(苏州)生物科技有限公司 一种新型免疫佐剂及其制备方法和应用
TW202404643A (zh) * 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
TW202421200A (zh) * 2022-11-09 2024-06-01 大陸商同宜醫藥（蘇州）有限公司 透過施用配體－藥物偶聯體治療癌症
CN120813385A (zh) * 2023-03-23 2025-10-17 同宜医药（苏州）有限公司 通过施用配体-药物偶联体治疗卵巢癌
CN121001746A (zh) * 2023-04-26 2025-11-21 同宜医药（苏州）有限公司 一种配体-药物偶联体在治疗癌症中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU2002337954C1 (en) * 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
US20050171014A1 (en) * 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7119168B2 (en) 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
US7935677B2 (en) 2003-12-05 2011-05-03 Cedars-Sinai Medical Center Polymalic acid-based multi-functional drug delivery system
US20100166654A1 (en) 2004-12-03 2010-07-01 The Uab Research Foundation Single-Drug Multi-Ligand Conjugates for Targeted Drug Delivery
EP2374480A3 (en) 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
RU2009114154A (ru) * 2006-09-15 2010-10-20 Энзон Фармасьютикалз, Инк. (Us) Полимерные пролекарства с направленной доставкой, содержащие полифункциональные линкеры
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101224306B (zh) * 2008-02-20 2011-04-20 中山大学 叶酸-多肽复合物介导的靶向抗肿瘤前体药物及其制备方法
CN102231951A (zh) * 2008-11-17 2011-11-02 安龙制药公司 用于核酸传递系统的可释放的偶联物
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2012019121A2 (en) * 2010-08-06 2012-02-09 Board Of Trustees Of The University Of Illinois Multiplexed supramolecular assemblies for non-viral delivery of genetic material
SI2729179T1 (sl) 2011-06-06 2021-01-29 Starpharma Pty Ltd Makromolekule
CA3179537A1 (en) * 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Xten conjugate compositions and methods of making same
CN103372199B (zh) * 2012-04-16 2015-12-16 广州暨南大学医药生物技术研究开发中心 一种预防和治疗神经退行性疾病的新型脑部靶向制剂
JP6290187B2 (ja) * 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
GB201211309D0 (en) 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
EP2869847B1 (en) 2012-07-09 2017-12-06 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
BR112015012014A2 (pt) 2012-12-04 2017-07-11 Abbvie Inc proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
WO2014086835A1 (en) 2012-12-05 2014-06-12 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
MX2015013163A (es) * 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CN106132431A (zh) 2013-10-15 2016-11-16 索伦托治疗有限公司 具有靶向分子和两种不同药物的药物偶联物
CN104784699B (zh) * 2014-01-20 2019-05-03 博瑞生物医药（苏州）股份有限公司 叶酸受体结合配体-药物偶联物
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN104667292B (zh) * 2015-02-02 2017-09-05 北京大学 一种还原响应型药物偶联物纳米粒的制备及其应用
CA2985823A1 (en) * 2015-05-12 2016-11-17 Blinkbio, Inc. Silicon based drug conjugates and methods of using same
MX381031B (es) * 2015-08-11 2025-03-12 Coherent Biopharma | Ltd Conjugados fármaco-multiligando y usos de los mismos.
JP2020164335A (ja) * 2019-03-28 2020-10-08 イビデン株式会社 ハニカム構造体

Also Published As

Publication number Publication date
ES2877409T3 (es) 2021-11-16
JP2018529632A (ja) 2018-10-11
CN111617250A (zh) 2020-09-04
US11571480B2 (en) 2023-02-07
AU2019240611B2 (en) 2021-09-09
EP3334500B1 (en) 2021-04-07
CA2987322A1 (en) 2017-02-16
KR102464778B1 (ko) 2022-11-07
RU2018104266A3 (enExample) 2019-09-12
KR20200071152A (ko) 2020-06-18
EP3334500A4 (en) 2019-04-03
MX2018001723A (es) 2018-05-17
US20180200377A1 (en) 2018-07-19
CN108135881A (zh) 2018-06-08
JP2021006549A (ja) 2021-01-21
JP2023025151A (ja) 2023-02-21
WO2017025057A1 (en) 2017-02-16
HK1250634A1 (zh) 2019-01-11
RU2722449C2 (ru) 2020-06-01
AU2016305703A1 (en) 2017-11-23
JP7573401B2 (ja) 2024-10-25
US20240100175A1 (en) 2024-03-28
MX381031B (es) 2025-03-12
EP3334500A1 (en) 2018-06-20
CN111617250B (zh) 2022-07-01
CN108135881B (zh) 2020-11-13
RU2018104266A (ru) 2019-09-12
KR20180033513A (ko) 2018-04-03
AU2016305703B2 (en) 2019-07-25
JP6772199B2 (ja) 2020-10-21
AU2019240611A1 (en) 2019-10-17
CA2987322C (en) 2020-02-11
DK3334500T3 (da) 2021-06-21
CN112263683A (zh) 2021-01-26
KR102301596B1 (ko) 2021-09-14

Similar Documents

Publication Publication Date Title
IL290457A (en) Antibodies and their conjugates
ZA201707464B (en) Multi-ligand drug conjugates and uses thereof
IL258248A (en) Attraction Oligonucleotide Conjugates and Their Uses
SI3592393T1 (sl) Sprostljivi konjugati
IL257615A (en) Aldehyde conjugates and their uses
IL250711A0 (en) Conjugates containing cell-binding agents and cytotoxic agents
IL265471A (en) Pulling-oligonucleotide conjugates and their uses
IL252015A0 (en) Antibody drug conjugates
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
IL254027A0 (en) cd48 antibodies and their conjugates
PL3148591T3 (pl) Koniugaty nanocząstka-lek
PT3271329T (pt) Novos ligantes hidrofílicos e conjugados ligando-fármaco dos mesmos
ZA201707475B (en) Compositions comprising antibody-duocarmycin drug conjugates
IL258759A (en) Anti-cd3-folate conjugates and their uses
ZA201608327B (en) Curcumin-peptide conjugates and formulations thereof
ZA201704709B (en) Antibody-urease conjugates for therapeutic purposes
GB201614443D0 (en) Targeted drug conjugates
IL262036A (en) Hyaluronic acid conjugates and uses thereof
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
LU92659B1 (en) Glycooptimized antibody drug conjugates
GB201615725D0 (en) Novel cytotoxic agents and conjugates thereof
GB201818562D0 (en) Pyrrolobenzodiazephones and conjugates thereof
GB201517852D0 (en) Novel compounds and conjugates
GB201418984D0 (en) Novel drug conjugates
GB201603124D0 (en) Novel compounds and conjugates